Drugs / IBI346 Antibody
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05266768 | Apr 2022 → Feb 2024 | refractory plasma cell neoplasm | Chunrui Li | Unknown | No outcome recorded |
| Phase 1 | NCT05270928 | Apr → Dec 2022 | refractory plasma cell neoplasm | The First Affiliated Hospital of Soochow University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI346 Antibody | “IBI346 Antibody and IBI346 CAR-T cell injection” NCT05270928 ↗1“IBI346 Antibody and IBI346 CAR-T cell injection” NCT05266768 ↗ |
| Modality | Protein / enzyme biologic | “IBI346 Antibody and IBI346 CAR-T cell injection” NCT05270928 ↗ |